Cargando…
Children with malignant melanoma: a single center experience from Turkey
AIM: Malignant melanoma is the most frequent skin cancer in children and adolescents. It comprises 1–3% of all malignancies. In this study, we aimed to evaluate the clinical aspects, histopathologic features, and treatment outcomes of our patients with malignant melanoma. MATERIAL AND METHODS: Patie...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kare Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096563/ https://www.ncbi.nlm.nih.gov/pubmed/32231448 http://dx.doi.org/10.14744/TurkPediatriArs.2019.90022 |
_version_ | 1783510835809746944 |
---|---|
author | Bay, Sema Büyükkapu Görgün, Ömer Kebudi, Rejin |
author_facet | Bay, Sema Büyükkapu Görgün, Ömer Kebudi, Rejin |
author_sort | Bay, Sema Büyükkapu |
collection | PubMed |
description | AIM: Malignant melanoma is the most frequent skin cancer in children and adolescents. It comprises 1–3% of all malignancies. In this study, we aimed to evaluate the clinical aspects, histopathologic features, and treatment outcomes of our patients with malignant melanoma. MATERIAL AND METHODS: Patients aged <15 years who were treated between 2003 and 2018 for malignant melanoma were retrospectively analyzed. RESULTS: Seventeen patients (10 females, 7 males), with a median age of 7 years (range, 7 months-13 years) were evaluated. Five patients had congenital melanocytic nevi. All had cutaneous melanoma except one with mucosal (conjunctival) melanoma. The most frequent primary tumor site was the lower extremities (35%). Sentinel lymphoscintigraphy, sentinel node biopsy, and PET/CT were performed as the staging procedures at initial diagnosis. Localized disease was present in eight patients; nine had regional lymph node metastasis. The only treatment was surgery in localized disease; surgery and adjuvant interferon treatment was given in patients with regional lymph node metastasis. Three developed distant metastasis (bone, lung, brain) at a median of 9 months. A three-year-old patient received a BRAF inhibitor (vemurafenib), and a 13-year-old patient received a check point inhibitor (ipilimumab); both died of progressive disease. The median follow-up for all patients was 25 months. The 5-year overall survival was 76.6%. CONCLUSION: Although malignant melanoma is rare in children, prognosis is good if diagnosed early. Physicians should be aware of skin lesions and full-layer biopsy should be obtained in suspicious skin lesions. Patients with congenital melanocytic nevi should also be followed up cautiously. |
format | Online Article Text |
id | pubmed-7096563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Kare Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-70965632020-03-30 Children with malignant melanoma: a single center experience from Turkey Bay, Sema Büyükkapu Görgün, Ömer Kebudi, Rejin Turk Pediatri Ars Original Article / Özgün Araştırma AIM: Malignant melanoma is the most frequent skin cancer in children and adolescents. It comprises 1–3% of all malignancies. In this study, we aimed to evaluate the clinical aspects, histopathologic features, and treatment outcomes of our patients with malignant melanoma. MATERIAL AND METHODS: Patients aged <15 years who were treated between 2003 and 2018 for malignant melanoma were retrospectively analyzed. RESULTS: Seventeen patients (10 females, 7 males), with a median age of 7 years (range, 7 months-13 years) were evaluated. Five patients had congenital melanocytic nevi. All had cutaneous melanoma except one with mucosal (conjunctival) melanoma. The most frequent primary tumor site was the lower extremities (35%). Sentinel lymphoscintigraphy, sentinel node biopsy, and PET/CT were performed as the staging procedures at initial diagnosis. Localized disease was present in eight patients; nine had regional lymph node metastasis. The only treatment was surgery in localized disease; surgery and adjuvant interferon treatment was given in patients with regional lymph node metastasis. Three developed distant metastasis (bone, lung, brain) at a median of 9 months. A three-year-old patient received a BRAF inhibitor (vemurafenib), and a 13-year-old patient received a check point inhibitor (ipilimumab); both died of progressive disease. The median follow-up for all patients was 25 months. The 5-year overall survival was 76.6%. CONCLUSION: Although malignant melanoma is rare in children, prognosis is good if diagnosed early. Physicians should be aware of skin lesions and full-layer biopsy should be obtained in suspicious skin lesions. Patients with congenital melanocytic nevi should also be followed up cautiously. Kare Publishing 2020-03-09 /pmc/articles/PMC7096563/ /pubmed/32231448 http://dx.doi.org/10.14744/TurkPediatriArs.2019.90022 Text en Copyright: © 2020 Turkish Archives of Pediatrics http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Original Article / Özgün Araştırma Bay, Sema Büyükkapu Görgün, Ömer Kebudi, Rejin Children with malignant melanoma: a single center experience from Turkey |
title | Children with malignant melanoma: a single center experience from Turkey |
title_full | Children with malignant melanoma: a single center experience from Turkey |
title_fullStr | Children with malignant melanoma: a single center experience from Turkey |
title_full_unstemmed | Children with malignant melanoma: a single center experience from Turkey |
title_short | Children with malignant melanoma: a single center experience from Turkey |
title_sort | children with malignant melanoma: a single center experience from turkey |
topic | Original Article / Özgün Araştırma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096563/ https://www.ncbi.nlm.nih.gov/pubmed/32231448 http://dx.doi.org/10.14744/TurkPediatriArs.2019.90022 |
work_keys_str_mv | AT baysemabuyukkapu childrenwithmalignantmelanomaasinglecenterexperiencefromturkey AT gorgunomer childrenwithmalignantmelanomaasinglecenterexperiencefromturkey AT kebudirejin childrenwithmalignantmelanomaasinglecenterexperiencefromturkey |